



Welcome to the Survey of Statewide and Territorial Drug Court Coordinators

Practices and Policies Relating to Medication-Assisted Treatment for Opioid Use Disorders in Adult Drug Courts

Thank you for participating in our survey. We would like to know which, if any, medications are being used in drug courts to treat opioid use disorders. The following questions pertain to **adult drug courts** in your state or territory. This may include hybrid adult drug courts that, for example, also serve persons charged with DWI or those with co-occurring disorders. It does not include stand-alone DWI courts, juvenile drug courts, family drug courts, veteran's treatment courts, mental health courts, or other types of treatment courts.

Responses will be reported in the aggregate and will **not** be attributed to any individual state or territory.

[Start Survey](#)

inquisium
by Cvent

[Privacy Policy](#)



0%

***1. How many adult drug courts are there in your state or territory?**

***2. Are you aware of the top five substances used most frequently during the most recent 12 months by participants prior to entering your state or territory's adult drug courts?**

- Yes
- No

[NEXT](#)

inquisium
by Cvent

[Privacy Policy](#)



4%

Substances Frequency

The question below asks that you rank up to five substances used most frequently by participants prior to entering your state or territory's adult drug courts (with 1 being the most frequent).

Please note, if you are unsure of the top five, please answer to the best of your ability.

For example, if you are only aware of the top three substances used most frequently, select these and then select "No additional substances 4" as your fourth and "No additional substances 5" as your fifth.

If you are still unsure how to answer this question, please contact Elizabeth Perkins at eperkins@ndci.org.

***3. During the most recent 12 months, please rank-order up to five (5) substances used most frequently by participants prior to entering your state or territory's adult drug courts (with 1 being the most frequent):**

	1	2	3	4	5
Alcohol	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Marijuana	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical opioids (e.g., Oxycodone, Vicodin, codeine)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Heroin or other nonpharmaceutical opiates (e.g., opium)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Fentanyl (including carfentanil)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cocaine	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Crack cocaine	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical sedatives (e.g., benzodiazepines, barbiturates)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical stimulants (e.g., Ritalin, Dexedrine, Adderall)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methamphetamine (e.g., "ice" or "crystal")	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Synthetic cannabinoids (e.g., K2, Spice)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hallucinogens (e.g., LSD, peyote, psilocybin mushrooms)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
PCP (e.g., phencyclidine, Angel Dust)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Club drugs (e.g., MDMA, GHB)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Inhalants (e.g., model glue, aerosols)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Dextromethorphan (cough syrup)

Other



No additional substances 2



No additional substances 3



No additional substances 4



No additional substances 5



4. If you selected "Other," please describe here:

***5. Is this answer based on:**

- Actual statewide or territorial data
- An informed estimate (e.g., based on individual program evaluations or data)
- Anecdotal information (e.g., reports or impressions of program coordinators)

PREVIOUS

NEXT

inquisium
by Quest

[Privacy Policy](#)



13%

***6. During the most recent 12 months, approximately what percentage of adult drug court participants in your state or territory had a moderate to severe opioid use disorder?**

- Unknown or Unable to answer
- None
- Very few (less than 10%)
- Some (about 25%)
- About half
- Most (about 75%)
- All or Nearly all

[PREVIOUS](#) [NEXT](#)



15%

***7. During the most recent 12 months, has there been a substantial change in the prevalence of opioid use among adult drug court participants in your state or territory? (Please check all that apply.)**

- This information is not available
- Use of pharmaceutical opioids has increased
- Use of pharmaceutical opioids has decreased
- No apparent change in the use of pharmaceutical opioids
- Use of illicit opioids has increased
- Use of illicit opioids has decreased
- No apparent change in the use of illicit opioids

***8. Is this answer based on:**

- Actual statewide or territorial data
- An informed estimate (e.g., based on individual program evaluations or data)
- Anecdotal information (e.g., reports or impressions of program coordinators)

PREVIOUS

NEXT



20%

***9. Among your adult drug court participants with an opioid use disorder, what is the primary type of opioid problem seen?**

- This information is not available
- Pharmaceutical opioids based on a legal prescription
- Pharmaceutical opioids without a prescription
- Illicit opioids (e.g., heroin, fentanyl, carfentanyl)

[PREVIOUS](#)

[NEXT](#)



22%

***10. Approximately what proportion of adult drug courts in your state or territory refer clients and/or permit clients to receive some form of medication-assisted treatment (MAT) for participants with an opioid use disorder?**

- Unknown or Unable to answer
- None
- Very few (less than 10%)
- Some (about 25%)
- About half
- Most (about 75%)
- All or Nearly all

***11. Does your state or territory have policies governing the use of MAT for opioid use disorder in adult drug courts?**

- Yes
- No
- Our state or territory is in the process of developing uniform policies governing the use of MAT in adult drug courts
- Don't know

[PREVIOUS](#)

[NEXT](#)



27%

***12. Please respond to each policy listed:**

	Yes	No	I don't know
*MAT is permitted only in limited cases, such as for the treatment of pregnant women.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*All adult drug courts are required to receive formal training on MAT for opioid use disorders.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*All adult drug courts are required to evaluate participants with opioid use disorders for their suitability for MAT.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Adult drug courts are required to permit participants to continue MAT previously prescribed for opioid use disorder.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Adult drug courts are permitted to begin MAT for new participants who have an opioid use disorder.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Adult drug courts are required to permit the use of naltrexone (e.g., Revia, Depade, Vivitrol) but not other medications such as buprenorphine or methadone.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Adult drug courts are prohibited from admitting participants receiving buprenorphine or methadone.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

***13. Approximately how long ago were these uniform policies governing the use of MAT for opioid use disorders enacted or most recently revised/updated?**

- Within the past year
- In the past 1-2 years
- 3 or more years ago
- Unknown or unable to answer



31%

***14. Is MAT available for participants in your state or territory's adult drug courts?**

- Yes, MAT is available in our state or territory.
- No, MAT is not available in our state or territory.

[PREVIOUS](#)

[NEXT](#)

inquisium
by Civet

[Privacy Policy](#)

***18. Approximately what proportion of adult drug courts in your state or territory require participants to discontinue use of the following medications as a condition of graduation from the program?**

	Unknown or Unable to answer	Very few or None	Some (about 25%)	About half	Most (about 75%)	All or Nearly all
*Methadone	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Naltrexone (e.g., ReVia, Depade, Vivitrol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

***19. In the most recent 12 months, approximately what proportion of adult drug court participants with an opioid use disorder graduated from the program while still receiving the following medications?**

	Unknown or Unable to answer	Very few or None	Some (about 25%)	About half	Most (about 75%)	All or Nearly all
*Methadone	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Naltrexone (e.g., ReVia, Depade, Vivitrol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

***20. Approximately what proportion of adult drug courts in your state or territory only allow the use of the following medications for pregnant women?**

	Unknown or Unable to answer	Very few or None	Some (about 25%)	About half	Most (about 75%)	All or Nearly all
*Methadone	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

***21. Are these answers based on:**

- Actual statewide or territorial data
- An informed estimate (e.g., based on individual program evaluations or data)
- Anecdotal information (e.g., reports or impressions of program coordinators)
- Unknown or unable to answer



50%

***22. Approximately what proportion of your state or territory's adult drug courts have naloxone (e.g., Narcan, EVISIO) available onsite at the drug court for participants experiencing an overdose?**

- Unknown or Unable to answer
- None
- Very few (less than 10%)
- Some (about 25%)
- About half
- Most (about 75%)
- All or Nearly all

***23. Approximately what proportion of your state or territory's adult drug courts provide training to their participants on how to use naloxone (e.g., Narcan, EVISIO) to reverse an overdose?**

- Unknown or Unable to answer
- None
- Very few (less than 10%)
- Some (about 25%)
- About half
- Most (about 75%)
- All or Nearly all

***24. Approximately what proportion of your state or territory's adult drug courts provide naloxone kits to participants in their program?**

- Unknown or Unable to answer
- None
- Very few (less than 10%)
- Some (about 25%)
- About half
- Most (about 75%)
- All or Nearly all

***25. Is your state or territory considering expanding the availability of MAT for opioid use disorders in adult drug courts?**

- Not applicable; MAT is already used in all adult drug courts
- Not considering expansion
- Undecided on expansion
- Definitely considering expansion

***26. To what extent do the views or opinions of personnel working in your adult drug courts limit the utilization of MAT?**

- Not at all
- Slightly
- Moderately
- Greatly

***27. To what extent do the views or opinions of external policy makers or administrators limit the utilization of MAT in your adult drug courts?**

- Not at all
- Slightly
- Moderately
- Greatly

PREVIOUS

NEXT

inquisium
by Civet

[Privacy Policy](#)



63%

***28. Are you aware of the top three (3) factors that limit the use of MAT for opioid use disorder or certain types of medications (buprenorphine or methadone), in your state or territory's adult drug courts?**

- Yes
- No

[PREVIOUS](#) [NEXT](#)



65%

Limiting Factors to the Use of MAT for Opioid Use Disorder

The question below asks that you rank up to three factors that limit the use of MAT for opioid use disorder or certain types of medication (buprenorphine or methadone), in your state or territory's adult drug courts (with 1 being the most influential limitation).

Please note, if you are unsure of the top three, please answer to the best of your ability.

For example, if you are only aware of the top two limiting factors, select these and then select "No additional limiting factors 3" as your third.

If you are still unsure how to answer this question, please contact Elizabeth Perkins at eperkins@ndci.org.

***29. Please rank-order the three (3) top factors that limit the use of MAT for opioid use disorder or certain types of medications (buprenorphine or methadone), in your state or territory's adult drug courts (with 1 being the most influential limitation):**

	1	2	3
Refusal or disinterest from participants	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Philosophy of local treatment providers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Insufficient funding	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Insufficient pool of qualified MAT providers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of knowledge of or familiarity with MAT by drug court staff	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Prohibitions from external (outside the drug court) policy makers or administrators	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Insufficient resources to prevent misuse or diversion (e.g., pill counts, observed ingestion)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Insufficient access to training or technical assistance on MAT	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Use of other substances by participants that may interact dangerously with methadone or buprenorphine (e.g., benzodiazepines, alcohol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other (please describe):	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
No additional limiting factors 2	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
No additional limiting factors 3	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

30. Other (please describe):

PREVIOUS

NEXT

inquisium
by CVent

[Privacy Policy](#)



72%

***31. In the last 10 years, has your state or territory been subject to civil judgments or administrative penalties related to the delivery of MAT for treatment of opioid use disorder in the criminal justice system?**

- Yes
- No
- Unknown or unable to answer
- Other - please describe:

32. If yes, please describe:

[PREVIOUS](#) [NEXT](#)



77%

***33. Is your state or territory currently involved in pending or ongoing litigation related to the delivery or non-delivery of MAT for the treatment of opioid use disorders?**

- Yes
- No
- Unknown or unable to answer

34. If yes, please describe:

***35. In the past five years, have there been any funding mandates or mechanisms in your state or territory to expand the use of MAT for opioid use disorders in drug courts?**

- Yes
- No
- Unknown or unable to answer

36. If yes, please describe:

***37. In the past five years, have there been any changes in your state or territorial certification procedures for treatment providers to administer MAT for opioid use disorders?**

- Yes
- No
- Unknown or unable to answer

38. If yes, please describe:

***39. Approximately what proportion of adult drug courts in your state or territory received training to implement or improve the delivery of MAT for opioid use disorders to participants?**


- Unknown or Unable to answer
- None
- Very few (less than 10%)
- Some (about 25%)
- About half
- Most (about 75%)
- All or Nearly all

40. Please briefly describe any MAT training received by your state or territory's adult drug courts.

***41. If applicable, did this training help to expand the use of MAT for opioid use disorders or affect MAT practices in your state or territory's adult drug courts?**

- Not applicable; no MAT training was received
- No
- A little
- Moderately
- Greatly
- Unknown or unable to answer

42. Please briefly explain:



[PREVIOUS](#) | [FINISH](#)

inquisium
by Crest

[Privacy Policy](#)



Thank you for completing the Survey on . We appreciate your time immensely. Your information has been recorded and NDCI staff will be in touch with next steps, if applicable.



[Privacy Policy](#)